Important note: Information in this article was accurate in October 2004. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 5, No. 9/10, October/November 2004
HIVandHepatits.com
Identification of basic prognostic indicators of HIV infection is essential before widespread antiretroviral therapy can be implemented in low-technology settings. This study assessed how well body mass index (BMI:kg/m2) predicts survival.
BMI within 3 months of HIV diagnosis was obtained from 1657 patients aged ≥15 years, recruited in a seroprevalent clinical cohort in The Gambia, West Africa, since 1992 and followed up at least once.
Baseline CD4+ counts and clinical assessment at time of diagnosis were done. The mortality hazard ratio (HR) of those with a baseline BMI <18 compared with those with a baseline BMI ≥18 was 3.4.
The median survival time of those presenting with a BMI <16 was 0.8 years, in contrast to a median survival of 8.9 years for those with a baseline BMI ≥22.
Baseline BMI <18 remained a highly significant independent predictor of mortality after adjustment for age, sex, co-trimoxazole prophylaxis, tuberculosis, reported wasting at diagnosis, and baseline CD4+ cell count.
Sensitivity and specificity of baseline BMI <18 was comparable to that of a CD4+ count <200 in predicting mortality within 6 months of diagnosis
The authors conclude: “BMI at diagnosis is a strong, independent predictor of survival in HIV-infected patients in West Africa … In the absence of sophisticated clinical and laboratory support, BMI may also prove a useful guide for deciding when to initiate antiretroviral therapy.”
The investigators also note that these study results have significant implications for drug treatment in developing countries. They conclude, “BMI at diagnosis is a low-technology, affordable, prognostic indicator, independent of age, sex, CD4 cell count, or HIV type.”
Source: HIVandHepatits.com
Ref: van der Sande M et al. Body Mass Index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1288-1294.
http://www.hivandhepatitis.com/recent/developing/100404_a.html
041010
IB040510-05
Copyright © 2004 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted: publisher@HIVandHepatitis.com ©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
